IRLAB Therapeutics (IRLAB) Q2 2025 earnings summary

Executive summary

• Advanced pipeline with five drug candidates for Parkinson's and CNS diseases, including three in clinical and two in preclinical development.

• Achieved key milestones: positive Phase I results for IRL757, new US patent for mesdopetam extending exclusivity into the mid-2040s, and expanded patent protection for pirepemat.

• Strengthened financial position with a SEK 115.7 million rights issue and expanded loan agreements.

• Focused on advancing partnerships, licensing, and business development for lead assets.

• Leadership transition with a new interim CFO appointed.

Financial highlights

• Cash position at quarter-end was SEK 54 million, with an additional SEK 56 million from the rights issue to be added in Q3.

• Net sales for H1 2025 were SEK 23.9 million, down from SEK 42.8 million year-over-year, with all revenue from the Otsuka collaboration for IRL757.

• Operating loss widened to SEK -54.4 million from SEK -42.7 million year-over-year.

• Cash flow from operating activities was SEK -36.3 million, slightly improved from SEK -38.1 million year-over-year.

• Equity turned negative at SEK -27.7 million, compared to SEK 69.7 million a year earlier.

Outlook and guidance

• Phase III initiation planned for mesdopetam, pending partnership, with regulatory alignment achieved.

• IRL757 Phase Ib study in Parkinson’s apathy to begin dosing in Q4, with results expected in 18 months.

• Pirepemat dose optimization study decision expected, with further studies planned.

• Preclinical projects IRL942 and IRL1117 prioritized, aiming for Phase I readiness in 2026.

• Focus on business development and asset partnering in the coming year.